Jiangsu Aosaikang Pharmaceutical (ASK) of Nanjing purchased a 5% stake in a New Zealand pharma, Living Cell Technologies, for $1.7 million. LCT’s major product, Diabecell, is a technology that implants encapsulated islet cells from pigs into the livers of diabetic patients. The product is in a Phase II clinical trial in New Zealand. As part of the investment, ASK will have an option on China rights to the technology. More details....